Holen Sie sich die Stockscreener-App
1.60
2.56%
0.04
Handel nachbörslich:
1.62
0.02
+1.25%
Cabaletta Bio Inc Aktie (CABA) Neueste Nachrichten
Analysts Set Cabaletta Bio, Inc. (NASDAQ:CABA) PT at $20.33 - MarketBeat
Cabaletta Bio's SWOT analysis: CAR-T pioneer's stock faces market skepticism - Investing.com Australia
Cabaletta Bio’s SWOT analysis: CAR-T pioneer’s stock faces market skepticism - Investing.com Australia
Cabaletta Bio’s SWOT analysis: CAR-T pioneer’s stock faces market skepticism By Investing.com - Investing.com South Africa
Cantor Fitzgerald Weighs in on Cabaletta Bio FY2026 Earnings - MarketBeat
Cabaletta Bio's (CABA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Cabaletta Bio Reports Promising Data from RESET Trials for Transformative Autoimmune Therapy - MSN
Cabaletta Bio stock price target reiterated on strong clinical data By Investing.com - Investing.com India
Cabaletta Bio stock price target reiterated on strong clinical data - Investing.com
Cabaletta Bio Prices Public Offering to Raise $100 Million - MSN
Cabaletta Bio Announces Public Offering of Common Stock and Warrants - MSN
H.C. Wainwright reiterates buy rating on Cabaletta Bio stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates buy rating on Cabaletta Bio stock - Investing.com Australia
Cabaletta Bio’s (CABA) Buy Rating Reaffirmed at HC Wainwright - Defense World
Analysts Offer Predictions for Cabaletta Bio FY2026 Earnings - Defense World
Cabaletta Bio Launches Public Offering Of Stock And Warrants - Nasdaq
Cabaletta Bio (CABA) Shares Drop 20% After Public Offering Annou - GuruFocus
Cabaletta Bio (CABA) Showcases Promising Rese-cel Data at EULAR 2025 | CABA Stock News - GuruFocus
Cabaletta Bio announces public offering of common stock and warrants By Investing.com - Investing.com South Africa
Cabaletta Bio prices $100 million public offering of shares and warrants By Investing.com - Investing.com South Africa
Cabaletta reports positive clinical data for autoimmune cell therapy By Investing.com - Investing.com South Africa
Cabaletta Bio looks to raise $100M in stock sale to fund cell therapy development - The Business Journals
Cabaletta Bio (CABA) Receives Reiterated Buy Rating from HC Wain - GuruFocus
Cabaletta Bio (CABA) Receives Reiterated Buy Rating from HC Wainwright & Co. | CABA Stock News - GuruFocus
Cabaletta Bio shares CAR-T results in three autoimmune conditions - Endpoints News
Cabaletta Bio Prices Securities Offering; Shares Fall - MarketScreener
Cabaletta Bio stock tumbles after pricing $100 million public offering By Investing.com - Investing.com Nigeria
Cabaletta Bio stock tumbles after pricing $100 million public offering - Investing.com Australia
Cabaletta Bio Announces Pricing of Public Offering of Securities - GuruFocus
Cabaletta Bio prices $100 million public offering of shares and warrants - Investing.com
Cabaletta Bio: Sector Headwinds And Funding Issues, But Also Some Clear Clinical Direction - Seeking Alpha
Cabaletta Bio announces public offering of common stock and warrants - Investing.com
Cabaletta Bio (CABA) Launches Public Offering with Warrants | CABA Stock News - GuruFocus
Cabaletta Bio Announces Proposed Public Offering of Securities | - GuruFocus
Cabaletta Bio Announces Proposed Public Offering of Securities - The Manila Times
Cabaletta Bio Announces Proposed Public Offering of Securities | CABA Stock News - GuruFocus
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in - GuruFocus
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress | CABA Stock News - GuruFocus
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress - The Manila Times
Cabaletta reports positive clinical data for autoimmune cell therapy - Investing.com
Breakthrough: New Autoimmune Therapy Achieves Drug-Free Remission in 94% of Trial Patients - Stock Titan
Cabaletta Bio Stockholders Approve Key Proposals - TipRanks
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):